GTS Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
GTS Securities's MDGL Position: Q3 2026 in Review
GTS Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 392 shares — an estimated $210K sold.
GTS Securities first reported a position in MDGL in Q3 2023 and held it in 6 quarters. The position peaked at $1.31M in Q3 2024. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- GTS Securities reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- GTS Securities sold 392 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $210K.
- GTS Securities first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 6 quarters.
- GTS Securities's Madrigal Pharmaceuticals position peaked at $1.31M in Q3 2024.
- 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.